206 related articles for article (PubMed ID: 31143951)
1. Biomarkers identified by serum metabolomic analysis to predict biologic treatment response in rheumatoid arthritis patients.
Takahashi S; Saegusa J; Onishi A; Morinobu A
Rheumatology (Oxford); 2019 Dec; 58(12):2153-2161. PubMed ID: 31143951
[TBL] [Abstract][Full Text] [Related]
2. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis.
Cuppen BV; Fu J; van Wietmarschen HA; Harms AC; Koval S; Marijnissen AC; Peeters JJ; Bijlsma JW; Tekstra J; van Laar JM; Hankemeier T; Lafeber FP; van der Greef J;
PLoS One; 2016; 11(9):e0163087. PubMed ID: 27631111
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
Akiyama M; Kaneko Y; Kondo H; Takeuchi T
Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
[TBL] [Abstract][Full Text] [Related]
5. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study.
Nakamura S; Suzuki K; Iijima H; Hata Y; Lim CR; Ishizawa Y; Kameda H; Amano K; Matsubara K; Matoba R; Takeuchi T
Arthritis Res Ther; 2016 Jul; 18():159. PubMed ID: 27435242
[TBL] [Abstract][Full Text] [Related]
6. Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.
Virone A; Bastard JP; Fellahi S; Capeau J; Rouanet S; Sibilia J; Ravaud P; Berenbaum F; Gottenberg JE; Sellam J
RMD Open; 2019; 5(2):e000897. PubMed ID: 31413865
[TBL] [Abstract][Full Text] [Related]
7. Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis.
Nguyen MVC; Baillet A; Romand X; Trocmé C; Courtier A; Marotte H; Thomas T; Soubrier M; Miossec P; Tébib J; Grange L; Toussaint B; Lequerré T; Vittecoq O; Gaudin P
Joint Bone Spine; 2019 Mar; 86(2):195-201. PubMed ID: 29885551
[TBL] [Abstract][Full Text] [Related]
8. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
[TBL] [Abstract][Full Text] [Related]
9. Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis.
Luque-Tévar M; Perez-Sanchez C; Patiño-Trives AM; Barbarroja N; Arias de la Rosa I; Abalos-Aguilera MC; Marin-Sanz JA; Ruiz-Vilchez D; Ortega-Castro R; Font P; Lopez-Medina C; Romero-Gomez M; Rodriguez-Escalera C; Perez-Venegas J; Ruiz-Montesinos MD; Dominguez C; Romero-Barco C; Fernandez-Nebro A; Mena-Vazquez N; Marenco JL; Uceda-Montañez J; Toledo-Coello MD; Aguirre MA; Escudero-Contreras A; Collantes-Estevez E; Lopez-Pedrera C
Front Immunol; 2021; 12():631662. PubMed ID: 33833756
[No Abstract] [Full Text] [Related]
10. Non-TNF inhibitor switchers versus TNF inhibitor cyclers from multicentre rheumatoid arthritis ultrasonography prospective cohort in Japan.
Endo Y; Kawashiri SY; Morimoto S; Nishino A; Okamoto M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Tada Y; Kawakami A
Immunol Med; 2020 Sep; 43(3):115-120. PubMed ID: 32393150
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive.
Harrold LR; Wittstock K; Kelly S; Han X; Zhuo J; Schrader A; Middaugh N; Moore PC; Khaychuk V
Adv Rheumatol; 2024 Jan; 64(1):10. PubMed ID: 38243281
[TBL] [Abstract][Full Text] [Related]
12. Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study.
Chen SK; Liao KP; Liu J; Kim SC
Arthritis Care Res (Hoboken); 2020 Jan; 72(1):9-17. PubMed ID: 30570833
[TBL] [Abstract][Full Text] [Related]
13. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
[TBL] [Abstract][Full Text] [Related]
14. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
[TBL] [Abstract][Full Text] [Related]
15. Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis.
Alemao E; Postema R; Elbez Y; Mamane C; Finckh A
Clin Exp Rheumatol; 2020; 38(3):455-466. PubMed ID: 31770089
[TBL] [Abstract][Full Text] [Related]
16. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.
Manders SH; Kievit W; Adang E; Brus HL; Moens HJ; Hartkamp A; Hendriks L; Brouwer E; Visser H; Vonkeman HE; Hendrikx J; Jansen TL; Westhovens R; van de Laar MA; van Riel PL
Arthritis Res Ther; 2015 May; 17(1):134. PubMed ID: 25997746
[TBL] [Abstract][Full Text] [Related]
18. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
20. The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study.
Pope JE; Rampakakis E; Sampalis J
Semin Arthritis Rheum; 2015 Apr; 44(5):499-505. PubMed ID: 25440158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
